A randomized phase II non-comparative study of PF-04691502 and gedatolisib (PF-05212384) in patients with recurrent endometrial cancer.

Del Campo, Josep María; Birrer, Michael; Davis, Craig; Fujiwara, Keiichi; Gollerkeri, Ashwin; Gore, Martin; Houk, Brett; Lau, Susie; Poveda, Andres; González-Martín, Antonio; Muller, Carolyn; Muro, Kei; Pierce, Kristen; Suzuki, Mie; Vermette, Jennifer; Oza, Amit.
Gynecol Oncol; 142(1): 62-69, 2016 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-27103175